Evidence map›Paper›PMID 34586475›Full record

Observational studyEuropean journal of pediatrics2022

Elevated liver enzymes of newly diagnosed pediatric celiac patients-a prospective-observational study.

Asaf Regev, Amir Ben-Tov, Anat Yerushalmy-Feler, Yael Weintraub, Hadar Moran-Lev, Shlomi Cohen, Achiya Z Amir

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Long-term laboratory follow-up is essential in pediatric patients with celiac.Journal of pediatric gastroenterology and nutrition · 2025
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Asaf RegevPediatrics, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. assafre84@gmail.com.ORCID http://orcid.org/0000-0001-5383-3223
Amir Ben-TovThe Pediatric Gastroenterology, Hepatology & Nutrition Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Anat Yerushalmy-FelerThe Pediatric Gastroenterology, Hepatology & Nutrition Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Yael WeintraubThe Pediatric Gastroenterology, Hepatology & Nutrition Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Hadar Moran-LevThe Pediatric Gastroenterology, Hepatology & Nutrition Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Shlomi CohenThe Pediatric Gastroenterology, Hepatology & Nutrition Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Achiya Z AmirThe Pediatric Gastroenterology, Hepatology & Nutrition Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. achiyaa@tlvmc.gov.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Celiac disease clinical presentation is constantly changing. We set to determine the prevalence of elevated transaminases in newly diagnosed celiac patients and to evaluate this sub-group of patients for associated clinical and laboratory findings and assess their natural course of disease following therapeutic diet initiation. We conducted a prospective-observational study of all newly diagnosed pediatric celiac patients, between August 2016 and April 2018, in a pediatric gastroenterology clinic. Clinical data, anthropometrics, and blood test results were recorded at diagnosis and at 3, 6, and 12 months, respectively, of follow-up. We compared patients with normal and elevated transaminases at diagnosis. ALT threshold was set at 24 U/l. Of 125 newly diagnosed celiac patients, 31 (24.8%) had elevated ALT at diagnosis; two (1.6%) with over 3 × ULN. Patients with elevated ALT at diagnosis were significantly younger (mean age 5.5 (SD 3.4) vs. 7.3 (SD 3.7) years, p < 0.01) and more commonly presented with diarrhea (32.3% vs. 14.9%, p = 0.03). Eighty percent of patients with elevated ALT levels normalized their ALT within 3 months and all within 1 year. Following gluten-free diet initiation, patients with elevated ALT had similar clinical course, growth, serology normalization rate, and laboratory results, compared to patients with normal ALT over a 1-year follow-up. A single patient was simultaneously co-diagnosed with celiac disease and autoimmune hepatitis.Conclusion: Clinically significant ALT abnormalities are rare among newly diagnosed pediatric celiac patients. Significant elevations failing to normalize on a gluten-free diet should raise concern of a concomitant primary liver disease and warrant further investigations. What is Known: • Elevated liver enzymes may be an extra-intestinal manifestation of celiac disease. • Reported prevalences of ALT elevations among children with a new diagnosis of celiac disease ranges between 5 and 40%. What is New: • ALT elevations are present in 25% of children with a new diagnosis of celiac disease. • Significant elevations (>3 × ULN) are rare (1.6%). • Elevated liver enzymes are associated with earlier age at diagnosis. • The natural history of patients with elevated liver enzymes at diagnosis is comparable to those without.

Indexed as

Celiac DiseaseLiver DiseasesChildChild, PreschoolDiet, Gluten-FreeHumansProspective StudiesCeliac diseaseChildrenElevated liver enzymesHypertransaminasemia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.